Our experienced team is pioneering precision medicine targeting neurodegeneration. Deep knowledge of the biological mechanisms found in neurodegenerative diseases led us to develop and optimize cutting-edge complementary discovery technology platforms, Morphomer® and SupraAntigen®. They are the engines that advance our industry-leading pipeline of vaccines, antibodies, small molecules and diagnostics targeting proteinopathies of the central nervous system (CNS). Their agility allows for accelerated discovery and development of candidates targeting novel targets.